NeuroPace 過去の業績
過去 基準チェック /06
NeuroPaceは5.1%の年平均成長率で業績を伸ばしているが、Medical Equipment業界はgrowingで10.1%毎年増加している。売上は成長しており、年平均19.2%の割合である。
主要情報
5.09%
収益成長率
93.67%
EPS成長率
| Medical Equipment 業界の成長 | 8.90% |
| 収益成長率 | 19.18% |
| 株主資本利益率 | -112.79% |
| ネット・マージン | -21.47% |
| 前回の決算情報 | 31 Dec 2025 |
最近の業績更新
Recent updates
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
Jan 09
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Nov 19NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Sep 19NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 14NeuroPace: Volatile, Uncertain, But Promising
Jun 29Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Jun 19NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 13
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 07NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Jan 24After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
Dec 04Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
Nov 14Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Nov 07NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
Aug 03Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Apr 12NeuroPace: Picking Up The Pace
Feb 25Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Jan 22NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
Apr 17収支内訳
収支内訳
NeuroPace の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 25 | 100 | -21 | 66 | 28 |
| 30 Sep 25 | 95 | -24 | 64 | 27 |
| 30 Jun 25 | 89 | -26 | 61 | 26 |
| 31 Mar 25 | 84 | -25 | 57 | 25 |
| 31 Dec 24 | 80 | -27 | 57 | 24 |
| 30 Sep 24 | 76 | -28 | 57 | 23 |
| 30 Jun 24 | 72 | -30 | 56 | 22 |
| 31 Mar 24 | 69 | -32 | 56 | 21 |
| 31 Dec 23 | 65 | -33 | 55 | 21 |
| 30 Sep 23 | 60 | -38 | 55 | 20 |
| 30 Jun 23 | 55 | -42 | 54 | 21 |
| 31 Mar 23 | 49 | -46 | 52 | 22 |
| 31 Dec 22 | 46 | -47 | 51 | 22 |
| 30 Sep 22 | 44 | -47 | 50 | 22 |
| 30 Jun 22 | 43 | -43 | 46 | 21 |
| 31 Mar 22 | 45 | -39 | 43 | 20 |
| 31 Dec 21 | 45 | -36 | 39 | 18 |
| 30 Sep 21 | 45 | -30 | 34 | 17 |
| 30 Jun 21 | 47 | -26 | 32 | 16 |
| 31 Mar 21 | 42 | -26 | 28 | 15 |
| 31 Dec 20 | 41 | -24 | 28 | 16 |
| 31 Dec 19 | 37 | -30 | 30 | 18 |
質の高い収益: NPCEは現在利益が出ていません。
利益率の向上: NPCEは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: NPCEは利益を出していないが、過去 5 年間で年間5.1%の割合で損失を削減してきた。
成長の加速: NPCEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: NPCEは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 7.5% ) と比較することは困難です。
株主資本利益率
高いROE: NPCEは現在利益が出ていないため、自己資本利益率 ( -112.79% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/04/29 07:55 |
| 終値 | 2026/04/29 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
NeuroPace, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Michael Polark | Baird |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Yi Chen | H.C. Wainwright & Co. |